

- [4] Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. *Lancet Infect Dis* 2002;2:25-32.
- [5] Scott JA, Brooks WA, Peiris JS, Holtzman D, Mulholland EK. Pneumonia research to reduce childhood mortality in the developing world. *J Clin Invest* 2008;118:1291-300.
- [11] Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines* 5th ed: Saunders-Elsevier, 2008: 569-604.
- [49] Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. *Lancet Infect Dis* 2006;6:303-12.
- [51] Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. *Lancet* 2005;365:1139-46.
- [259] Greenwood BM, Weber MW, Mulholland K. Childhood pneumonia--preventing the worlds biggest killer of children. *Bull World Health Organ* 2007;85:502-3.
- [260] Mulholland K. Childhood pneumonia mortality--a permanent global emergency. *Lancet* 2007;370:285-9.
- [261] Black S, Eskola J, Whitney C, Shinefield H. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines* 5th ed. Philadelphia: Saunders-Elsevier, 2008: 531-67.
- [262] Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? *Lancet* 2003;361:2226-34.
- [263] Mulholland K. Magnitude of the problem of childhood pneumonia. *Lancet* 1999;354:590-2.
- [264] Peltola H. Burden of meningitis and other severe bacterial infections of children in africa: implications for prevention. *Clin Infect Dis* 2001;32:64-75.
- [265] Henrichsen J. Typing of *Streptococcus pneumoniae*: past, present, and future. *Am J Med* 1999;107:50S-4S.
- [266] Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. *Clin Infect Dis* 2000;30:100-21.
- [267] Coles CL, Kanungo R, Rahmathullah L, Thulasiraj RD, Katz J, Santosham M, et al. Pneumococcal nasopharyngeal colonization in young South Indian infants. *Pediatr Infect Dis J* 2001;20:289-95.
- [268] Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. *J Infect Dis* 1999;180:1171-6.
- [269] Decousser JW, Ovetchkine P, Collignon A, Chaplain C, Estrangin E, Fremaux A, et al. Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive *Streptococcus pneumoniae* invasive isolated from children in the Ile de France area. *Eur J Clin Microbiol Infect Dis* 2004;23:27-33.
- [270] INPES. Direction Générale de la Santé, Guide des Vaccinations. Edition 2006 ed. Saint-Denis, France, 2006.
- [271] Boisier P, Mainassara HB, Sidikou F, Djibo S, Kairo KK, Chanteau S. Case-fatality ratio of bacterial meningitis in the African meningitis belt: we can do better. *Vaccine* 2007;25 Suppl 1:A24-9.
- [272] Obaro SK. Prospects for pneumococcal vaccination in African children. *Acta Trop* 2000;75:141-53.
- [273] Brent AJ, Ahmed I, Ndiritu M, Lewa P, Ngetsa C, Lowe B, et al. Incidence of clinically significant bacteraemia in children who present to hospital in Kenya: community-based observational study. *Lancet* 2006;367:482-8.
- [274] Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, Lloyd-Evans N, et al. Outcome of meningitis caused by *Streptococcus pneumoniae* and *Haemophilus influenzae* type b in children in The Gambia. *Trop Med Int Health* 2000;5:207-13.
- [275] Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. *Am J Respir Crit Care Med* 2002;165:766-72.

- [276] Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention. *J Infect Dis* 1994;170:368-76.
- [277] Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive pneumococcal disease in central Australia. *Med J Aust* 1995;162:182-6.
- [278] Ortqvist A, Hedlund J, Kalin M. *Streptococcus pneumoniae*: epidemiology, risk factors, and clinical features. *Semin Respir Crit Care Med* 2005;26:563-74.
- [279] Hart CA, Beeching NJ, Duerden BI, Curry A, French N, Kariuki S, et al. Infections in AIDS. *J Med Microbiol* 2000;49:947-67.
- [280] Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. *Clin Infect Dis* 2001;33:158-65.
- [281] French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet* 2000;355:2106-11.
- [282] Gilks CF, Ojoo SA, Ojoo JC, Brindle RJ, Paul J, Batchelor BI, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. *Lancet* 1996;347:718-23.
- [283] Bridy-Pappas AE, Margolis MB, Center KJ, Isaacman DJ. *Streptococcus pneumoniae*: description of the pathogen, disease epidemiology, treatment, and prevention. *Pharmacotherapy* 2005;25:1193-212.
- [284] Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of *Haemophilus influenzae* type b and pneumococcal type 6A polysaccharide-protein conjugates. *Infect Immun* 1983;40:245-56.
- [285] Fiore AE, Levine OS, Elliott JA, Facklam RR, Butler JC. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. *Emerg Infect Dis* 1999;5:828-31.
- [286] Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *N Engl J Med* 1991;325:1453-60.
- [287] Kumar D, Chen MH, Wong G, Cobos I, Welsh B, Siegal D, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. *Clin Infect Dis* 2008;47:885-92.
- [288] Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. *BMC Infect Dis* 2008;8:53.
- [289] Vila-Corcoles A. Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia? *Lancet Infect Dis* 2008;8:405-6.
- [290] Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. *Vaccine* 2008;26:1955-62.
- [291] Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. *CMAJ* 2009;180:48-58.
- [292] O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? *Lancet Infect Dis* 2007;7:597-606.
- [293] Lehmann D, Pomat WS, Riley ID, Alpers MP. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. *Vaccine* 2003;21:3446-50.
- [294] Healy CM, Baker CJ. Prospects for prevention of childhood infections by maternal immunization. *Curr Opin Infect Dis* 2006;19:271-6.
- [295] Vila-Corcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly? *Drugs Aging* 2007;24:791-800.
- [296] de Roux A, Schmolle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults:

- conjugate vaccine elicits improved antibacterial immune responses and immunological memory. *Clin Infect Dis* 2008;46:1015-23.
- [297] Esposito S, Lizioli A, Lastrico A, Begliatti E, Rognoni A, Tagliabue C, et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. *Respir Res* 2007;8:12.
- [298] Vestrheim DF, Lovoll O, Aaberge IS, Caugant DA, Hoiby EA, Bakke H, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. *Vaccine* 2008;26:3277-81.
- [299] Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. *Pediatr Infect Dis J* 2000;19:187-95.
- [300] O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. *Lancet* 2003;362:355-61.
- [301] Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, et al. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *Pediatr Infect Dis J* 2006;25:306-11.
- [302] Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). *Vaccine* 2007;25:2194-212.
- [303] Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. *N Engl J Med* 2001;344:403-9.
- [304] Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Jr., Pelton SI. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. *Vaccine* 2006;24:2514-20.
- [305] Fletcher MA, Fritzell B. Brief review of the clinical effectiveness of PREVENAR against otitis media. *Vaccine* 2007;25:2507-12.
- [306] Benninger MS. Acute bacterial rhinosinusitis and otitis media: changes in pathogenicity following widespread use of pneumococcal conjugate vaccine. *Otolaryngol Head Neck Surg* 2008;138:274-8.
- [307] Bliss SJ, O'Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. *Lancet Infect Dis* 2008;8:67-80.
- [308] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med* 2003;348:1737-46.
- [309] Azzari C, Resti M. Reduction of carriage and transmission of *Streptococcus pneumoniae*: the beneficial "side effect" of pneumococcal conjugate vaccine. *Clin Infect Dis* 2008;47:997-9.
- [310] McBean AM, Park YT, Caldwell D, Yu X. Declining invasive pneumococcal disease in the U.S. elderly. *Vaccine* 2005;23:5641-5.
- [311] Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. *Expert Rev Vaccines* 2006;5:651-67.
- [312] Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. *Vaccine* 2007;25:2451-7.
- [313] Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. *Pediatr Infect Dis J* 2006;25:312-9.
- [314] Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. *Lancet* 2007;369:389-96.

- [315] Bricks LF, Berezin E. Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. *J Pediatr (Rio J)* 2006;82:S67-74.
- [316] Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. *Lancet* 2001;357:950-2.
- [317] WHO, Initiative for vaccine research. What serotypes cause pneumococcal disease among children around the world? Proceedings of the 9 th Global Vaccine Research Forum Paris; 2008 June
- [318] WHO, Initiative for Vaccine Research. Serotype distribution of invasive pneumococcal isolates and anti-microbial resistance patterns in south Asian countries Proceedings of the 7 th Global Vaccine Research Forum Bangkok; 2006 December
- [319] Schuerman L, Prymula R, Henckaerts I, Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. *Vaccine* 2007;25:1962-8.
- [320] Prymula R, Chlibek R, Splino M, Kaliskova E, Kohl I, Lommel P, et al. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. *Vaccine* 2008;26:4563-70.
- [321] Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. *J Infect Dis* 2002;185:927-36.
- [322] O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. *J Infect Dis* 2007;196:1211-20.
- [323] Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. *JAMA* 2007;297:1784-92.
- [324] Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. *Jama* 2004;291:2197-203.
- [325] Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. *Clin Infect Dis* 2008;46:174-82.
- [326] Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. *Vaccine* 2007;25:2963-73.
- [327] Barocchi MA, Ries J, Zogaj X, Hemsley C, Albiger B, Kanth A, et al. A pneumococcal pilus influences virulence and host inflammatory responses. *Proc Natl Acad Sci U S A* 2006;103:2857-62.
- [328] Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. *Crit Rev Microbiol* 2006;32:139-53.
- [329] Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. *Infect Immun* 2007;75:350-7.
- [330] Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. *J Infect Dis* 2000;182:1694-701.
- [331] Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. *J Infect Dis* 2003;188:339-48.
- [332] Hollingshead SK, Baril L, Ferro S, King J, Coan P, Briles DE. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. *J Med Microbiol* 2006;55:215-21.

[\[333\]](#) Hamel J, Charland N, Pineau I, Ouellet C, Rioux S, Martin D, et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. *Infect Immun* 2004;72:2659-70.